Mindfulness meditation + progressive muscle relaxation
Mindfulness meditation + progressive muscle relaxation has been studied in 1 paper since 2024: 1 trial in people. The newest paper, May 17, 2024: “The influence of mindfulness meditation combined with progressive muscle relaxation training on the clinical efficacy and quality of life of patients with sarcopenia receiving haemodialysis: a randomised controlled trial”.
1 paper studies it8 findingsUpdated
See all 1 papers on mindfulness meditation + progressive muscle relaxation
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“When comparing the intervention group with the control group, all physical ability indicators in the intervention group showed significant improvements (32.68 ± 8.32 vs 26.50 ± 6.83; 37.42 ± 10.12 vs 28.12 ± 8.51; 19.8 ± 5.40 vs 25.29 ± 7.18), and the differences were statistically significant (p < 0.05”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave mindfulness meditation + progressive muscle relaxation to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves exercise capacity32.68 ± 8.32 vs 26.50 ± 6.83; 37.42 ± 10.12 vs 28.12 ± 8.51; 19.8 ± 5.40 vs 25.29 ± 7.18 up: Improves quality of life61.30 ± 5.38 vs 42.98 ± 5.73; 57.50 ± 3.55 vs 50.70 ± 3.62 up: Increases albumin | Randomized trial12 weeks | 49 people58.8 ± 14.9 yearsPatients with sarcopenia receiving maintenance haemodialysis | BMC complementary medicine and therapies, May 17, 2024 |
What did studies of mindfulness meditation + progressive muscle relaxation find?
4Studies of mindfulness meditation + progressive muscle relaxation measured 4 outcomes, among them albumin, inflammation and quality of life.
Albumin
upin humans1
1 study
Albumin
upin humans1
Mindfulness meditation + progressive muscle relaxation increases albumin in patients with sarcopenia receiving haemodialysis.
“When comparing the intervention with the control group, after 12 weeks, the intervention group showed improvements in physical abilities, KDQOLTM scores in the PF, RP, CH, Energy, SPL, SL, DSE, Pain, CF, EWB and PS dimensions, as well as serum inflammation indicators (hs-CRP, IL-1) and nutrition indicators (ALB and PA), and the improvements were significant compared to before the intervention (p < 0.05”
Human trialin patients with sarcopenia receiving haemodialysis12 weeksn = 49
BMC complementary medicine and therapies
Mindfulness meditation + progressive muscle relaxation increases albumin in humans (patients with sarcopenia receiving maintenance haemodialysis) (30.62 ± 1.65 vs 35.60 ± 1.68; 0.32 ± 0.05 vs 0.44 ± 0.07, p < 0.05).
“albumin and prealbumin levels were significantly increased compared with the baseline (30.62 ± 1.65 vs 35.60 ± 1.68; 0.32 ± 0.05 vs 0.44 ± 0.07) (p < 0.05)”
Human trialpatients with sarcopenia receiving maintenance haemodialysis12 weeks
BMC complementary medicine and therapies
Inflammation
downin humans1
1 study
Inflammation
downin humans1
Mindfulness meditation + progressive muscle relaxation decreases inflammation in patients with sarcopenia receiving haemodialysis.
“When comparing the intervention with the control group, after 12 weeks, the intervention group showed improvements in physical abilities, KDQOLTM scores in the PF, RP, CH, Energy, SPL, SL, DSE, Pain, CF, EWB and PS dimensions, as well as serum inflammation indicators (hs-CRP, IL-1) and nutrition indicators (ALB and PA), and the improvements were significant compared to before the intervention (p < 0.05”
Human trialin patients with sarcopenia receiving haemodialysis12 weeksn = 49
BMC complementary medicine and therapies
Mindfulness meditation + progressive muscle relaxation decreases inflammation in humans (patients with sarcopenia receiving maintenance haemodialysis) (30.29 ± 2.96 vs 17.65 ± 3.22; 8.93 ± 0.99 vs 3.02 ± 0.34).
“Some inflammatory markers, such as the levels of interleukin-6 and high-sensitivity C-reactive protein (30.29 ± 2.96 vs 17.65 ± 3.22; 8.93 ± 0.99 vs 3.02 ± 0.34), showed a decrease during the intervention”
Human trialpatients with sarcopenia receiving maintenance haemodialysis12 weeks
BMC complementary medicine and therapies
Quality of life
upin humans1
1 study
Quality of life
upin humans1
Mindfulness meditation + progressive muscle relaxation improves quality of life in patients with sarcopenia receiving haemodialysis (61.30 ± 5.38 vs 42.98 ± 5.73; 57.50 ± 3.55 vs 50.70 ± 3.62).
“After 12 weeks, the patients' quality of life, as measured by KDQOLTM, was significantly higher in terms of KDTA and SF-36 total scores compared to before the intervention and in the control group (61.30 ± 5.38 vs 42.98 ± 5.73; 57.50 ± 3.55 vs 50.70 ± 3.62) (p < 0.01).”
Human trialin patients with sarcopenia receiving haemodialysis12 weeksn = 49
BMC complementary medicine and therapies
Mindfulness meditation + progressive muscle relaxation improves quality of life in humans (patients with sarcopenia receiving maintenance haemodialysis) (p < 0.05).
“When compared with the control group, the intervention group showed significant improvements in 10 dimensions of exercise capacity and KDQOLTM scores”
Human trialpatients with sarcopenia receiving maintenance haemodialysis12 weeks
BMC complementary medicine and therapies
Exercise capacity
upin humans1
1 study
Exercise capacity
upin humans1
Mindfulness meditation + progressive muscle relaxation improves exercise capacity in patients with sarcopenia receiving haemodialysis (32.68 ± 8.32 vs 26.50 ± 6.83; 37.42 ± 10.12 vs 28.12 ± 8.51; 19.8 ± 5.40 vs 25.29 ± 7.18).
“When comparing the intervention group with the control group, all physical ability indicators in the intervention group showed significant improvements (32.68 ± 8.32 vs 26.50 ± 6.83; 37.42 ± 10.12 vs 28.12 ± 8.51; 19.8 ± 5.40 vs 25.29 ± 7.18), and the differences were statistically significant (p < 0.05”
Human trialin patients with sarcopenia receiving haemodialysis12 weeksn = 49
BMC complementary medicine and therapies
Mindfulness meditation + progressive muscle relaxation improves exercise capacity in humans (patients with sarcopenia receiving maintenance haemodialysis) (p < 0.05).
“Exercise capacity (sit-to-stand test,handgrip,time to 10 sit-ups) significantly improved in the intervention group after 12 weeks”
Human trialpatients with sarcopenia receiving maintenance haemodialysis12 weeks
BMC complementary medicine and therapies